Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.

Until 2024, the preferred first-line treatment for epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) advanced non-small cell lung cancer (NSCLC) was osimertinib, a third-gene...

Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Results from the phase 3 PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (Ex20ins) mutations. The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Li et al. assess the safety and early efficacy of an intracranially autologous cell therapy combined with chemotherapy in patients with refractory brain metastases and glioblastomas, demonstrating tolerability alongside preliminary efficacy signals. Exploratory cerebrospinal fluid analyses reveal treatment-associated immune activation and tumor dynamics, offering early biological rationale for the strategy.

Ocrelizumab Secures Expanded Approval for Pediatric Multiple SclerosisRoche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-re...

Read the full paper: Pemetrexed potentiates γδ T cell-based immunotherapy in NSCLC through ATM-STING-NF-κB-mediated induction of NKG2D ligands

As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS and a ...

Lantern Pharma Inc., an AI-driven precision oncology company, today reported clinical data and updates in the form of a presentation from its ongoing Phase 2 HARMONIC™ trial evaluating LP-300 in combination with carboplatin and pemetrexed in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who have progressed following TKI-based...

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.

United States Pemetrexed Market By Application: In-Depth Analysis The U.S. pemetrexed market primarily caters to oncology therapeutics, with applications spanning multiple cancer types. The key segmen...

Integrated spatial, bulk, and single-cell transcriptomics identify para-tumor field-cancerized fibroblasts as drivers of pemetrexed resistance in lung adenocarcinoma. Genetic disruption of tumor-cell CD44 and ITGA3–ITGB1 signaling restores chemosensitivity in patient-derived organoids, establishing a functionally validated tri-component platform for precision targeting of tumor-stroma interactions in LUAD.